ArticleJournal of cosmetic dermatology2026
Postbiotic_Loaded Hyalurosome: Investigating Their Potential as Antimicrobial and Antioxidant Agents.
Article in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineering Multi-Scale Transdermal Delivery Systems for Atopic Dermatitis: Emerging Insights from the Gut-Skin Axis.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe skin microbiota supports skin health by defending against pathogens and regulating immunity, while its imbalance can lead to disorders. With rising interest in natural ingredients, postbiotics (bioactive metabolites from probiotic fermentation) are emerging as natural antimicrobial and antioxidant agents.
aimsThis study evaluates the antibacterial and antioxidant properties of cell-free supernatants (CFS) from four lactic acid bacteria (LAB) (Lacticaseibacillus rhamnosus [LGG], Limosilactobacillus reuteri [LR], Limosilactobacillus fermentum [LF], and Weizmannia coagulans [WCO]) and encapsulates the two most potent samples (one with the highest antibacterial and the other with the strongest antioxidant activity) into hyaluronic acid-based nanoparticles (hyalurosome) for enhanced topical delivery.
methodsGrowth curve analysis, supernatant preparation, antibacterial assays (determination of minimum inhibitory concentration [MIC], minimum bactericidal concentration [MBC], and inhibition zone), antioxidant assay (measuring the scavenging activities of 2,2-diphenyl-1-picrylhydrazyl [DPPH assay]), nanoparticle synthesis and characterization, and cytotoxicity testing were performed.
resultsLGG demonstrated potent, broad-spectrum antibacterial activity, showing the highest efficacy against Micrococcus luteus (M. luteus) (30 mm inhibition zone, MIC/MBC of 5/7.5% v/v). In contrast, WCO exhibited superior antioxidant capacity, with an IC₅₀ of 17.48 μg/mL in the DPPH assay, outperforming ascorbic acid (IC₅₀ = 32.50 μg/mL). The optimized hyalurosomes were spherical, monodisperse (80-200 nm, PDI < 0.7), and retained the bioactivity of the postbiotics. LGG-hyalurosomes achieved complete eradication of M. luteus and Staphylococcus aureus (S. aureus) within 48 h, demonstrating sustained release, while WCO-hyalurosomes maintained strong antioxidant activity (IC₅₀ = 37.63 μg/mL). Crucially, encapsulation significantly reduced cytotoxicity, increasing human dermal fibroblast viability from 60% (free CFS) to over 90% at a 6.25% (v/v) concentration.
conclusionThese results position LAB-derived postbiotics delivered via hyalurosomes as a potent and safe dual-function strategy, addressing both microbial dysbiosis and oxidative stress in advanced skincare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.